Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week High – Should You Buy?

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) reached a new 52-week high on Monday . The company traded as high as $28.00 and last traded at $27.9710, with a volume of 228286 shares. The stock had previously closed at $26.87.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on BCAX shares. Wells Fargo & Company increased their price target on Bicara Therapeutics from $11.00 to $16.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 31st. Morgan Stanley lifted their price objective on shares of Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 12th. Wall Street Zen upgraded shares of Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, May 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Wednesday, April 8th. Finally, Wedbush restated an “outperform” rating and set a $30.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $30.27.

Bicara Therapeutics Price Performance

The company’s 50-day moving average is $22.37 and its two-hundred day moving average is $19.49. The firm has a market cap of $1.95 billion, a P/E ratio of -10.68 and a beta of -0.53.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). On average, analysts expect that Bicara Therapeutics Inc. will post -3.48 EPS for the current fiscal year.

Insider Activity

In other Bicara Therapeutics news, CFO Ivan Hyep sold 9,200 shares of the firm’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $20.42, for a total value of $187,864.00. Following the sale, the chief financial officer owned 145,355 shares of the company’s stock, valued at approximately $2,968,149.10. This trade represents a 5.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Raben sold 5,500 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $22.88, for a total value of $125,840.00. Following the completion of the sale, the insider directly owned 55,286 shares in the company, valued at approximately $1,264,943.68. This represents a 9.05% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 63,900 shares of company stock valued at $1,420,704. 13.80% of the stock is owned by insiders.

Institutional Trading of Bicara Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of BCAX. AQR Capital Management LLC bought a new position in Bicara Therapeutics in the first quarter valued at about $248,000. Woodline Partners LP raised its stake in Bicara Therapeutics by 26.5% during the first quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock worth $4,543,000 after acquiring an additional 72,998 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Bicara Therapeutics by 36.8% in the second quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock worth $6,248,000 after acquiring an additional 180,833 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Bicara Therapeutics by 26.0% in the second quarter. JPMorgan Chase & Co. now owns 27,458 shares of the company’s stock worth $255,000 after acquiring an additional 5,664 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock valued at $29,000 after purchasing an additional 1,233 shares in the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.